Licensing status

Publication and contact information



Dipeptidyl peptidase-4 (DPP-4)

Mouse studies suggest blocking DPP-4 could help prevent neutropenia during chemotherapy or radiation therapy. In mice receiving chemotherapy or radiotherapy, animals lacking Dpp-4 had greater hematopoietic progenitor cell (HPC) recovery than wild-type mice. In wild-type mice receiving radiation or chemotherapy, pretreatment with the DPP-4 inhibitor Januvia sitagliptin led to increased HPC and hematopoietic stem cell (HSC) recovery in bone marrow compared with vehicle pretreatment. Ongoing work includes identifying the best timing and dosing of Januvia or other DPP-4 inhibitors to enhance recovery of neutrophils and platelets after radiation, chemotherapy or stem cell transplantation.
Merck & Co. Inc. and Ono Pharmaceutical Co. Ltd. market Januvia to treat type 2 diabetes.
At least five other DPP-4 inhibitors are approved to treat type 2 diabetes.

SciBX 5(47); doi:10.1038/scibx.2012.1236
Published online Dec. 6, 2012

Patent pending; unlicensed

Broxmeyer, H.E. et al. Nat. Med.; published online Nov. 18, 2012;
Contact: Hal E. Broxmeyer, Indiana University School of Medicine, Indianapolis, Ind.